Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Features
<b>Part One of a Two-Part Article</b>. There are as many ways of settling marital estates as there are creative attorneys and divorcing couples. Each permutation brings its own complications, including tax burdens to be allocated (and avoided). When the assets are to be paid out by one party to the other over time rather than in lump-sum amount, the tax consequences of the arrangement must be carefully considered.
Features
More couples than ever are choosing to live together without benefit of marriage. Some simply reject the institution. Some are same-sex partners who cannot marry in New York or most other states. Others have been married previously and do not wish to jeopardize their separate governmental entitlements or to create marital rights that might conflict with their ability to control their separate property.
On June 20, 2005, the Supreme Court granted certiorari in an important case for intellectual property holders seeking to navigate the sometimes-conflicting dictates of patent and antitrust law. In <i>Independent Ink, Inc. v. Illinois Tool Works, Inc., and Trident, Inc.</i>, 396 F.3d 1492 (Fed. Cir. 2005), the U.S. Court of Appeals for the Federal Circuit held that a patent establishes a rebuttable presumption of market power in a tying case brought under Section 1 of the Sherman Act. The ruling has put the Federal Circuit at odds with several lower courts, the Antitrust Division of the Department of Justice, the Federal Trade Commission and a host of academic critics, each of which maintain that patent rights do not, by themselves, give rise to an inference of market power, and that any rule to the contrary has the potential to reduce legitimate incentives to innovate.
Features
On June 13, 2005, the U.S. Supreme Court expanded the safe harbor provision of 35 U.S.C. '271(e)(1) to the "use of patented compounds in preclinical studies ... as long as there is a reasonable basis for believing that the experiments will produce 'the types of information that are relevant to an [Investigational New Drug application ("IND")] or [New Drug Application ("NDA")].'" <i>Merck KGaA v. Integra Lifesciences I, Ltd.</i>, __ U.S. __, 125 S.Ct. 2372, 2383-84 (U.S. 2005) (quoting Brief of U.S. as Amicus Curiae 23) ("<i>Integra II</i>").
Enforcement strategies in an industrywide patent enforcement campaign may differ from strategies advantageous in a single litigation. In a single litigation scenario, the goal is to maximize the recovery in the present case without any consideration given to possible effects the present lawsuit may have on future cases. Although this may be somewhat shortsighted as the same players (plaintiff, defendant, and attorneys) are likely to cross paths again and their previous experience will undoubtedly affect their mutual expectations and behavior in subsequent encounters, in reality it is not taken into consideration as often as it should be. Not so in an industrywide enforcement campaign, where the goal is to maximize the monetary recovery for the patent or patent portfolio with respect to all infringers. In this scenario, each case must be considered not in isolation but in the context of the overall enforcement campaign.
Features
Everything contained in this issue in an easy-to-follow format.
Writ Of Assistance Upheld As to Non-Parties in Foreclosure Action Citibank, N.A. v. Plagakis NYLJ 8/15/05, p. 32, col. 1 AppDiv, Second Dept (memorandum…
A recent decision of the Supreme Court, N.Y. County, in a landlord-tenant dispute has highlighted the extreme difficulty facing an owner when a notice of pendency is filed against its realty in an action arguably affecting the title to, possession, use or enjoyment of, the owner's real property, CPLR ' 6501.